ArticleObstetrics and gynecology international2026
Association of Guillain-Barré Syndrome With Nonavalent Human Papillomavirus Vaccine: A Postmarketing Drug Safety Study.
Article in Obstetrics and gynecology international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Association of Guillain-Barré Syndrome With Nonavalent Human Papillomavirus Vaccine: A Postmarketing Drug Safety Study.Obstetrics and gynecology international · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Human papillomavirus (HPV) vaccines prevent types of HPV responsible for most cervical cancers. While Guillain-Barré syndrome (GBS) has rarely reported postvaccination, a causal relationship remains unestablished. This study evaluates the association between the nonavalent HPV vaccine (9-valent) and GBS using the Vaccine Adverse Event Reporting System (VAERS). Methods: We analyzed VAERS data from January 1, 2016, to July 26, 2024, focusing on domestic reports for individuals aged 6-29 years. GBS cases were identified using the MedDRA preferred term code 10018767. Disproportionality was assessed via a 2 × 2 contingency table to calculate the proportional reporting ratio (PRR) and Yates' chi-squared ( Results: A total of 11 serious GBS cases were reported following HPV 9-valent vaccination out of 14,367 total adverse events for the vaccine. Comparison with all other vaccines (1757 GBS cases) yielded a PRR of 0.79 (95% CI: 0.44-1.44) and a Yates' Conclusions: The findings indicate an absence of a disproportionality signal in VAERS, suggesting that GBS is not reported more frequently after HPV 9-valent than other vaccines. However, this study is limited by a small number of cases and the inherent constraints of passive surveillance; thus, these results reflect reporting patterns and cannot establish causality or absolute incidence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.